Ww Intl Inc Stock Price, News & Analysis

WeightWatchers (NASDAQ: WW) announced a collaboration with Amazon Pharmacy on October 20, 2025 to speed medication access for WeightWatchers Clinic members.

Key features include real-time medication availability, automatic manufacturer-sponsored savings at checkout, and fast home delivery including free two-day shipping for Prime and same-day delivery where eligible. The integration uses Amazon’s pharmacy infrastructure (licensed pharmacists, robotic vial-filling, smart routing) to simplify prescriptions for GLP-1s and other weight-management medications.

The release cites a WeightWatchers Clinic study showing members lost 21% body weight at 12 months, and says the partnership aims to pair medication access with the company’s clinical programs and coaching.

WeightWatchers (NASDAQ: WW) launched RxFlexFund on October 17, 2025, a new employer benefit model to expand GLP-1 access by combining direct manufacturer pricing, employer subsidies, and WeightWatchers clinical and behavioral support.

Employers pay for WeightWatchers Clinic and subsidize medication costs at a set rate of 25%–75%. Members receive FDA‑approved GLP‑1 prescriptions with obesity‑trained clinicians, nutrition and behavior programs, and registered dietitians. Company cites a 20% reduction in annual healthcare expenses linked to weight loss and a reported 46% boost in work‑related quality of life in a 6‑month trial (n=180).

WeightWatchers (NASDAQ: WW) published its 2025 WeightWatchers for Business Annual Report on Oct 15, 2025, highlighting measurable employer health outcomes and economic impact.

Key findings: 21% average weight loss at 12 months for WW Clinic patients prescribed GLP-1s; 46% improvement in work-related quality of life; 0.9-point HbA1c reduction at six months in a diabetes trial; 55% monthly engagement and 90% client satisfaction. Report notes ROI projections up to 4X and states some studies are company-funded or manuscripts under review.

WeightWatchers (NASDAQ: WW) has launched a pioneering menopause program featuring Queen Latifah as its first official spokeswoman. The comprehensive program, WeightWatchers for Menopause, combines medical care, nutrition support, and community resources to support women through perimenopause to post-menopause.

The program has demonstrated significant results, with menopausal women losing nearly 4x more weight than those managing independently. Members using WeightWatchers Clinic achieved an average 18.6% body weight loss (40.1 lbs) in one year. Research from Mayo Clinic showed postmenopausal women receiving hormone therapy with GLP-1 semaglutide achieved 30% greater weight loss compared to GLP-1 alone.

WeightWatchers (NASDAQ: WW) has appointed Alejandro Bethlen as Executive Vice President, International, to lead the company's global expansion efforts. Bethlen brings over two decades of experience in scaling consumer, e-commerce, and marketplace businesses worldwide, previously serving as Chief Merchandising Officer at Zooplus SE and holding senior roles at Amazon.

This strategic appointment comes as part of WeightWatchers' broader transformation, which includes recent leadership additions such as Dr. Kim Boyd as Chief Medical Officer, Uta Knablein as Chief Product Officer, and Julie Rice as Chief Experience Officer. The company aims to leverage its 50+ years of international presence and scientific expertise to expand its reach in global markets.

WeightWatchers (NASDAQ: WW) has launched its inaugural WeightWatchers Awards, recognizing 38 standout products in health and wellness that support weight management journeys. The awards, leveraging the company's 62-year legacy in science-backed weight management, were selected by a diverse panel of experts including registered dietitians, fitness experts, and program developers.

Products were evaluated across categories including food and drink, movement tools, and meal prep essentials. Notable winners include Good Culture® Cottage Cheese, Pyrex® Freshlock™ Glass Containers, and HOKA® Clifton 10 Sneakers. Selection criteria focused on nutritional quality, accessibility, affordability, and practical application in supporting sustainable health habits.

The initiative aims to simplify consumer choices in a crowded marketplace by highlighting products that combine expert recommendations with real-world member usage data collected through the WeightWatchers app from May 2024 to April 2025.

WeightWatchers (NASDAQ: WW) reported Q2 2025 results, marking a significant transformation following its strategic reorganization completion on June 24, 2025. The company successfully reduced debt by $1.15 billion. Combined revenues reached $189 million, down 6% year-over-year, with Clinical revenues growing 55% to $31 million. Total subscribers decreased 17% to 3.2 million, including 127,000 Clinical subscribers.

The company transitioned Clinical subscribers from compounded semaglutide to FDA-approved medications starting May 22nd. For fiscal 2025, WeightWatchers projects total combined revenues of $685-700 million and Adjusted EBITDA of $140-150 million.

WeightWatchers (NASDAQ: WW) has appointed Julie Rice, SoulCycle co-founder and longtime board member, as its new Chief Experience Officer. In this newly created position, Rice will lead the transformation of WeightWatchers' global workshop business, which currently conducts 20,000 meetings monthly across 11 markets.

Rice will oversee the integration of Peoplehood, her community-driven wellness platform, into WeightWatchers, incorporating its curriculum, technology, and learnings, particularly in GLP-1 and menopause-based community work. The company will enhance its workshop offerings with community-based programs focused on education, accountability, and behavioral change, supported by research showing that WeightWatchers workshop members lose twice as much weight as those attempting weight loss independently.

WeightWatchers (NASDAQ: WW) has rescheduled its second quarter 2025 earnings release and conference call. The delay is necessary to finalize the company's Fresh Start Accounting adoption following its emergence from financial reorganization on June 24, 2025.

Originally scheduled for August 5, 2025, the earnings release will now take place before market open on Monday, August 11, 2025, with a conference call at 8:30 a.m. ET the same day. The webcast will be available on the company's corporate website with a replay accessible for at least 90 days.